Sumatriptan/naproxen sodium (Treximet) vs Sumatriptan succinate (Zembrace SymTouch)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Migraine
Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline
Sumatriptan/naproxen sodium (Treximet)
Marketed by Azurity Pharmaceuticals and partners
NCT00488514 · Phase 3 · completed
The study was nonrandomized, open-label, and had no placebo or active comparator, although 656 adolescents were enrolled. Its posted primary safety endpoint found drug-related adverse events in 170 of 622 treated participants, but the uncontrolled design cannot establish how Treximet compares with no treatment or another migraine medicine.
No aligned efficacy figure on record for this race.
Sumatriptan succinate (Zembrace SymTouch)
Marketed by Tonix Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Sumatriptan/naproxen sodium (Treximet): registry results are on file for Migraine, but their comparison mappings are not yet available.
Sumatriptan succinate (Zembrace SymTouch): registry results are on file for Migraine, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sumatriptan/naproxen sodium (Treximet)'s landscape · Sumatriptan succinate (Zembrace SymTouch)'s landscape